Jim E Riviere
Overview
Explore the profile of Jim E Riviere including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
1969
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jaberi-Douraki M, Xu X, Dima D, Ailawadhi S, Anwer F, Mazzoni S, et al.
Blood Cancer J
. 2024 Dec;
14(1):223.
PMID: 39706832
Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial...
2.
Wu X, Chen Q, Chou W, Maunsell F, Tell L, Baynes R, et al.
Toxicol Sci
. 2024 Oct;
203(2):181-194.
PMID: 39475069
Flunixin meglumine is a nonsteroidal anti-inflammatory drug (NSAID). Banamine Transdermal is a pour-on formulation of flunixin approved for pain control in beef and dairy cattle, but not for calves and...
3.
Mi K, Chou W, Chen Q, Yuan L, Kamineni V, Kuchimanchi Y, et al.
J Control Release
. 2024 Aug;
374:219-229.
PMID: 39146980
Nanoparticles (NPs) can be designed for targeted delivery in cancer nanomedicine, but the challenge is a low delivery efficiency (DE) to the tumor site. Understanding the impact of NPs' physicochemical...
4.
Xu X, Riviere J, Raza S, Millagaha Gedara N, Ampadi Ramachandran R, Tell L, et al.
Expert Opin Drug Metab Toxicol
. 2024 Feb;
20(7):579-592.
PMID: 38299552
Introduction: Pharmacovigilance plays a pivotal role in monitoring adverse events (AEs) related to chemical substances in human/animal populations. With increasing spontaneous-reporting systems, researchers turned to approaches to efficiently analyze drug...
5.
Yuan L, Chen Q, Riviere J, Lin Z
J Drug Deliv Sci Technol
. 2023 Dec;
83.
PMID: 38037664
Nanoparticles (NPs) have been widely used in different areas, including consumer products and medicine. In terms of biomedical applications, NPs or NP-based drug formulations have been extensively investigated for cancer...
6.
Chen Q, Yuan L, Chou W, Cheng Y, He C, Monteiro-Riviere N, et al.
ACS Nano
. 2023 Oct;
17(20):19810-19831.
PMID: 37812732
Low tumor delivery efficiency is a critical barrier in cancer nanomedicine. This study reports an updated version of "Nano-Tumor Database", which increases the number of time-dependent concentration data sets for...
7.
Chou W, Tell L, Baynes R, Davis J, Cheng Y, Maunsell F, et al.
Food Chem Toxicol
. 2023 Sep;
181:114062.
PMID: 37769896
Humans can be exposed to per- and polyfluoroalkyl substances (PFAS) through dietary intake from milk and edible tissues from food animals. This study developed a physiologically based pharmacokinetic (PBPK) model...
8.
Zad N, Tell L, Ampadi Ramachandran R, Xu X, Riviere J, Baynes R, et al.
Food Chem Toxicol
. 2023 Jul;
179:113920.
PMID: 37506867
Establishing maximum-residue limits (MRLs) for veterinary medicine helps to protect the human food supply. Guidelines for establishing MRLs are outlined by regulatory authorities that drug sponsors follow in each country....
9.
Chou W, Chen Q, Yuan L, Cheng Y, He C, Monteiro-Riviere N, et al.
J Control Release
. 2023 Jul;
361:53-63.
PMID: 37499908
The critical barrier for clinical translation of cancer nanomedicine stems from the inefficient delivery of nanoparticles (NPs) to target solid tumors. Rapid growth of computational power, new machine learning and...
10.
Ampadi Ramachandran R, Tell L, Rai S, Millagaha Gedara N, Xu X, Riviere J, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242626
Data curation has significant research implications irrespective of application areas. As most curated studies rely on databases for data extraction, the availability of data resources is extremely important. Taking a...